Gankyrin: A potential target for drug therapy against hepatocellular carcinoma
Open Access
- 1 January 2012
- journal article
- Published by Scientific Research Publishing, Inc. in Journal of Biomedical Science and Engineering
- Vol. 05 (08), 469-475
- https://doi.org/10.4236/jbise.2012.58059
Abstract
Hepatocellular Carcinoma is a primary malignant tumor of the liver and gankyrin is an oncoprotein over-expressed in hepatocellular carcinoma. It has been found that Gankyrin protein reduces the level of p53 protein by increasing its ubiquitylation and degradation, following a MDM-2 mediated pathway. Interaction of gankyrin with MDM2 enhances the ubiquitylation of p53. Independent study of this protein molecule revealed that it is identical to the p28 subunit of the 26S proteasome, having seven similar alpha helical ankyrin repeats. Gankyrin also binds to the Tumor Suppressor Protein (TSP) Retinoblastoma (RB), thereby accelerating its phosphorylation and proteasomal degradation. Blocking the expression of Gankyrin with MDM2 in cases of Hepatocellular Carcinoma (HCC) promoted apoptosis in cancer cells. Hence, Gankyrin can be used as a potential target for drug therapy against Hepatocellular CarcinomaKeywords
This publication has 1 reference indexed in Scilit:
- Gankyrin: a new oncoprotein and regulator of pRb and p53Trends in Cell Biology, 2006